Use of ADCC-optimized antibodies for treating weak patients

Details for Australian Patent Application No. 2004261754 (hide)

International Classifications

Event Publications

16 February 2006 PCT application entered the National Phase

PCT publication WO2005/012358 Priority application(s): WO2005/012358

15 January 2009 Assignment before Grant

Laboratoire Francais Du Fractionnement et des Biotechnologies The application has been assigned to LFB Biotechnologies

23 December 2010 Application Accepted

Published as AU-B-2004261754

3 February 2011 Corrigenda

Applications Accepted - Name Index Under the name LFB Biotechnologies, Application No. 2004261754, under INID (72) add co-inventor Nony, Emmanuel

3 March 2011 Application for Amendment

The nature of the amendment is as shown in the statement(s) filed 14 Feb 2011. Address for service in Australia - Freehills Patent & Trade Mark Attorneys Level 38 MLC Centre Martin Place Sydney NSW 2000

30 June 2011 Amendment Made

The nature of the amendment is as shown in the statement(s) filed 14 Feb 2011

30 June 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.